These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 12084161

  • 1. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.
    Weusten JJ, van Drimmelen HA, Lelie PN.
    Transfusion; 2002 May; 42(5):537-48. PubMed ID: 12084161
    [Abstract] [Full Text] [Related]

  • 2. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J, Laperche S, Groupe "Agents Transmissibles par Transfusion" de la Société française de transfusion sanguine, Etablissement français du sang, Centre de transfusion sanguine des armées.
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [Abstract] [Full Text] [Related]

  • 3. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R.
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [Abstract] [Full Text] [Related]

  • 4. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.
    Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ, Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service.
    Transfusion; 2002 Oct; 42(10):1365-72. PubMed ID: 12423522
    [Abstract] [Full Text] [Related]

  • 5. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR, SIMTI Research Group.
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [Abstract] [Full Text] [Related]

  • 6. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L, AbdulRahman M, John TJ, AlHashimi A.
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations.
    Jackson BR, Busch MP, Stramer SL, AuBuchon JP.
    Transfusion; 2003 Jun; 43(6):721-9. PubMed ID: 12757522
    [Abstract] [Full Text] [Related]

  • 8. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ, German Red Cross NAT Study Group.
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [Abstract] [Full Text] [Related]

  • 9. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing.
    Offergeld R, Faensen D, Ritter S, Hamouda O.
    Euro Surveill; 2005 Feb; 10(2):8-11. PubMed ID: 15735310
    [Abstract] [Full Text] [Related]

  • 10. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
    Koch C, Araújo F.
    Acta Med Port; 2013 Feb; 26(4):371-6. PubMed ID: 24016646
    [Abstract] [Full Text] [Related]

  • 11. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM, Reta CB, Torres O, Celis A, Domínguez J.
    Salud Publica Mex; 2011 Feb; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [Abstract] [Full Text] [Related]

  • 12. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R, Lelie N, Busch M, Kleinman S, International NAT Study Group.
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [Abstract] [Full Text] [Related]

  • 13. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT, Field SP, Busch MP, Heyns Adu P.
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [Abstract] [Full Text] [Related]

  • 14. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
    El Ekiaby M, Moftah F, Goubran H, van Drimmelen H, LaPerche S, Kleinman S, Busch M, Lelie N.
    Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
    [Abstract] [Full Text] [Related]

  • 15. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003.
    Soldan K, Davison K, Dow B.
    Euro Surveill; 2005 Feb; 10(2):17-9. PubMed ID: 15735312
    [Abstract] [Full Text] [Related]

  • 16. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan.
    Mine H, Emura H, Miyamoto M, Tomono T, Minegishi K, Murokawa H, Yamanaka R, Yoshikawa A, Nishioka K, Japanese Red Cross NAT Research Group.
    J Virol Methods; 2003 Sep; 112(1-2):145-51. PubMed ID: 12951223
    [Abstract] [Full Text] [Related]

  • 17. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP.
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [Abstract] [Full Text] [Related]

  • 18. The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review.
    Wu D, Feng F, Wang X, Wang D, Hu Y, Yu Y, Huang J, Wang M, Dong J, Wu Y, Zhu H, Zhu F.
    BMC Infect Dis; 2022 Mar 23; 22(1):279. PubMed ID: 35321684
    [Abstract] [Full Text] [Related]

  • 19. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria.
    Whyte GS, Savoia HF.
    Med J Aust; 1997 Jun 02; 166(11):584-6. PubMed ID: 9201178
    [Abstract] [Full Text] [Related]

  • 20. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM, Unkelbach U, Chudy M, Seitz R.
    Transfusion; 2008 May 02; 48(5):822-6. PubMed ID: 18208414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.